类风湿关节炎患者启动与停用阿片类药物治疗的相关因素
基于澳大利亚风湿病协会数据库2001-2015年3225例成人RA患者(73%女性,平均年龄57岁,中位随访54个月),分析阿片类使用相关因素。随访5年内62%患者曾使用阿片类,人群平均现用 prevalence 33%(95%CI 32-34),高效价阿片类9%(95%CI 8-10)。疼痛、HAQ评分及口服糖皮质激素使用与启动阿片类概率升高及停用概率降低相关。
要点
- RA患者阿片类使用普遍,5年内曾用者达62%,现用者33%。
- 疼痛、HAQ评分高及口服糖皮质激素使用是启动阿片类的重要决定因素。
- NSAID和DMARD治疗与启动和停用阿片类的概率均降低相关。
核心结论
- RA患者中阿片类使用患病率高,与疼痛、功能和糖皮质激素治疗相关。
- NSAID和DMARD治疗可使部分但非全部患者免于阿片类需求。
研究设计与样本
- 成年RA患者(n=3225,73%女性,平均年龄57岁,中位随访54个月)于2001-2015年纳入澳大利亚风湿病协会数据库(ARAD)。
- 采用 logistic 回归分析时变协变量的个体内和个体间效应量,并用转移状态分析探讨与阿片类启动或停用相关的协变量。
主要发现
- 任何阿片类使用的人群平均患病率为33%(95%CI 32-34),高效价阿片类为9%(95%CI 8-10)。
- 随访5年后62%(95%CI 60-64)患者报告曾使用阿片类。
- 女性阿片类使用较高,随基线年龄增大而降低。
- 个体内阿片类使用与较高自报疼痛和HAQ评分(p<0.001)及NSAID(OR 1.88;95%CI 1.67-2.10)、口服糖皮质激素(OR 2.23;95%CI 1.93-2.58)、csDMARD(OR 2.08;95%CI 1.78-2.44)和bDMARD(OR 1.22;95%CI 1.06-1.40)治疗相关。
- 较低基线年龄、较高疼痛评分、HAQ评分和口服糖皮质激素使用是与阿片类使用改变相关的重要决定因素,与启动阿片类概率较高和停用概率较低相关;NSAID和DMARD治疗与启动和停用阿片类的概率均较低相关。
临床怎么用
- 对RA患者应关注疼痛和功能状态,并审慎评估口服糖皮质激素使用与阿片类启动风险的关系。
- 优化NSAID和DMARD治疗可能减少部分患者的阿片类需求,但需注意其与停用概率降低的 paradoxical 关联。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine factors associated with opioid use in rheumatoid arthritis (RA) patients. METHODS: Adult RA patients (n = 3225, 73% female, mean age 57 years, median follow-up 54 months) were recruited into the Australian Rheumatology Association Database (ARAD) between 2001-2015. A logistic regression examining both within- and between-patient effect sizes for time-varying covariates, and transition-state analysis for covariates associated with opioid commencement or cessation were used to examine determinants of current opioid use. RESULTS: The population-averaged prevalence of any opioid use was 33% (95%CI 32-34), 9% (95% CI 8, 10) for high potency opioid use, and 62% (95% 60, 64) of patients reported opioid ever-use after five years of follow-up. Opioid use was higher in females and decreased with older baseline age. Within-patients opioid use was associated with higher self-reported pain and HAQ scores (p < 0.001), and NSAID (OR 1.88; 1.67-2.10), oral glucocorticoid (2.23;1.93-2.58), csDMARD (2.08;1.78-2.44) and bDMARD (1.22;1.06-1.40) treatment. Younger baseline age, higher pain scores, HAQ scores and oral GC use were important determinants of change in opioid use, associated with both a higher probability of commencing opioid use, and a lower probability of cessation. Paradoxically, NSAID and DMARD treatments were associated with both a lower probability of commencing opioids, and a lower probability of cessation. CONCLUSIONS: There was a high prevalence of opioid use among RA patients, which was associated with pain, function and GC treatment. NSAID, and DMARD treatments obviate the need for opioids in some, but not all, patients.
引用
- Black RJ, Richards B, Lester S, et al. Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019. PMID: 31280936. doi:10.1016/j.semarthrit.2019.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。